COMMUNIQUÉS West-GlobeNewswire

Lirum Therapeutics Announces Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy Demonstrating Potent Preclinical Activity Against IGF-Related Cancers, Accepted for Presentation at the 2024 ESMO Sarcoma and Rare Cancers Congres
14/03/2024
New York, NY, March 14, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the [...]
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
14/03/2024
SEATTLE and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of [...]
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
14/03/2024
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic [...]
Konica Minolta Healthcare Sponsors SPIE Best Student Paper Award
14/03/2024
WAYNE, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas congratulates the winner and runners-up of the Best Student Paper Award given by the International Society for Optics and Photonics ( [...]
iSpecimen Reports Full Year 2023 Results
14/03/2024
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a [...]
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
14/03/2024
WASHINGTON, March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP , SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for [...]
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
14/03/2024
Dr. Zsuzsanna Devecseri, MD, MBA, is the Global Head, Medical Affairs, Oncology, Novartis DURHAM, United Kingdom and CAMBRIDGE, United Kingdom, March 14, 2024 (GLOBE NEWSWIRE) -- S. M. Discovery Group (SMDG), a [...]
Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
14/03/2024
All endpoints met for novel β₂-adrenoceptor agonist ATR-258 treating root cause of T2D SOLNA, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for [...]
IBEX Files Addendum to Management Proxy Circular for Sale of the Company at $1.45 Per Share
14/03/2024
MONTRÉAL, March 14, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) announces that it has filed an addendum to its management proxy circular dated February 23, 2024 for [...]
Bayer and Aignostics to collaborate on next generation precision oncology
14/03/2024
Not intended for UK Media Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development, further strengthening Bayer’s precision oncology [...]
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
14/03/2024
AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE [...]
Amolyt Pharma conclut un accord définitif visant son acquisition par AstraZeneca
14/03/2024
AstraZeneca fera l’acquisition d’Amolyt Pharma pour un total pouvant atteindre 1,05 milliard de dollars. L’opération devrait être finalisée au troisième trimestre de 2024. Lyon (France) et Cambridge, Massachusetts, 14 [...]
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
14/03/2024
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid [...]
Relation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm
14/03/2024
Relation Therap eutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm London, March 2024 – Relation Therapeutics, a biotechnology company at the forefront of leveraging [...]
PanTera signs a second agreement for the supply of actinium-225
14/03/2024
PanTera’s continues to deploy its strategy to become a market leader into the production and distribution of Ac225 Mol, Belgium, March 14, 2024: PanTera, the Belgian radioisotope producer created as a joint venture by [...]
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc.
14/03/2024
Enabling Technology Supports the Development of Anocca’s Deep Pipeline of TCR-T therapeutics NEW YORK and SÖDERTÄLJE, Sweden, March 14, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T cell receptor-engineered T [...]
Addex to Present at the Bio-Europe Spring 2024 Conference
14/03/2024
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, [...]
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
14/03/2024
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older This follows the first commercial launch of AGAMREE in [...]

Pages